0812 ET - Jazz Pharmaceuticals' $935 million deal to buy Chimerix carries a potential quick payoff in the form of an FDA priority review voucher. Chimerix's dordaviprone, which is under FDA review with an August 18 target action date, may be eligible for one of the vouchers, which the agency awards upon approval of drugs previously granted rare-pediatric-disease designation. The vouchers can be used to obtain priority review for another drug or sold to other companies, and a trio of recent deals has seen vouchers change hands at $150 million apiece. Chimerix rockets 70% premarket. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
March 05, 2025 08:12 ET (13:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。